Objective-The noncoding single-nucleotide polymorphism rs12740374 has been hypothesized to be the causal variant responsible for liver-specific modulation of SORT1 (sortilin 1) expression (ie, expression quantitative trait locus) and, by extension, the association of the SORT1 locus on human chromosome 1p13 with low-density lipoprotein cholesterol levels and coronary heart disease. The goals of this study were to compare 3 different hepatocyte models in demonstrating that the rs12740374 minor allele sequence is responsible for transcriptional activation of SORT1 expression. Approach and Results-We found that although primary human hepatocytes of varied rs12740374 genotypes strongly replicated the SORT1 expression quantitative trait locus observed previously in whole-liver samples, a population cohort of induced pluripotent stem cell-derived hepatocyte-like cells poorly replicated the expression quantitative trait locus. In primary human hepatocytes from multiple individuals heterozygous at rs12740374, we used CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) to specifically target the rs12740374 minor allele sequence ex vivo, resulting in a reproducible reduction in SORT1 expression. We generated a locus-humanized transgenic mouse with a bacterial artificial chromosome bearing the human SORT1 locus with the rs12740374 minor allele. In this mouse model, we used CRISPR-Cas9 to target the rs12740374 minor allele sequence in the liver in vivo, resulting in a substantial reduction of hepatic SORT1 expression. Conclusions-The rs12740374 minor allele sequence enhances SORT1 expression in hepatocytes. CRISPR-Cas9 can be used in primary human hepatocytes ex vivo and locus-humanized mice in vivo to interrogate the function of noncoding regulatory regions. Induced pluripotent stem cell-derived hepatocyte-like cells experience limitations that prevent faithful modelling of some hepatocyte expression quantitative trait loci. Visual Overview-An online visual overview is available for this article. (eg, HepG2, and Hep3B) are homozygous for the major allele of rs12740374 and thus should have no enhancement of SORT1 expression; 3 moreover, these cell lines do not represent authentic, fully functional hepatocytes. Adding to the challenge, the sequence surrounding rs12740374 in human chromosome 1p13 is poorly conserved in the orthologous region in the mouse genome, preventing the use of wild-type mice to study the rs12740374-SORT1 relationship in vivo.
L ow-density lipoprotein cholesterol (LDL-C) is one of the best-established causal risk factors for coronary heart disease. Genome-wide association studies have reproducibly identified a locus on human chromosome 1p13 as being strongly associated with both LDL-C and coronary heart disease. 1, 2 Within the locus, SORT1 (sortilin 1) has been established to be the causal gene responsible for modulation of blood LDL-C levels and, by extension, coronary heart disease risk. 3, 4 SORT1 regulates both the hepatic secretion of LDL particles into the bloodstream and the clearance of LDL particles from the bloodstream. 4, 5 The best candidate for the causal DNA variant responsible for the association of the SORT1 locus on chromosome 1p13 with LDL-C and coronary heart disease is rs12740374-a noncoding single-nucleotide polymorphism (SNP) that lies ≈120 kb away from the promoter of the SORT1 gene. 3 A series of experiments have suggested that the minor allele of rs12740374 creates a binding site for CCAAT enhancerbinding protein transcription factors, resulting in liver-specific transcriptional activation of SORT1, that is, a liver-specific expression quantitative trait locus (eQTL). However, these experiments did not demonstrate a direct causal link between rs12740374 and SORT1 by perturbing the site of the SNP in the genome and evoking an alteration of SORT1 expression. A significant challenge to achieving this is that the strong association between rs12740374 genotype and SORT1 expression has previously been observed only in liver and presumably is specific to hepatocytes. 3, 6 Indeed, querying of all 44 tissue
Interrogation of the Atherosclerosis-Associated SORT1 (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice types available in the GTEx (Gene-Tissue Expression) project's database (https://www.gtexportal.org/) as of the time of this writing shows evidence for a substantial eQTL only in liver. All commonly used cultured human hepatoma cell lines (eg, HepG2, HuH-7, and Hep3B) are homozygous for the major allele of rs12740374 and thus should have no enhancement of SORT1 expression; 3 moreover, these cell lines do not represent authentic, fully functional hepatocytes. Adding to the challenge, the sequence surrounding rs12740374 in human chromosome 1p13 is poorly conserved in the orthologous region in the mouse genome, preventing the use of wild-type mice to study the rs12740374-SORT1 relationship in vivo.
Here we use 3 hepatocyte model systems to interrogate the role of the hypothesized rs12740374 minor allele enhancer vis-à-vis human SORT1 expression. The first is a collection of primary human hepatocytes with varied rs12740374 genotypes. The second is a population cohort of induced pluripotent stem cell-derived hepatocyte-like cells (HLCs). The third is a mouse model in which the human SORT1 locus with the rs12740374 minor allele has been added to the genome via bacterial artificial chromosome (BAC) transgenesis. With 2 of the model systems, we use CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) ex vivo or in vivo to specifically target the rs12740374 minor allele sequence and assess for an effect on hepatic SORT1 expression, thus establishing complementary approaches to study human-specific regulatory regions in hepatocytes.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Of the genes in the SORT1 locus ( Figure 1A ), SORT1 and PSRC1 have previously been reported to display a strong correlation of expression levels with rs12740374 genotype in liver samples (with the minor allele associated with increased expression), with CELSR2 showing weaker correlation and SARS, MYBPHL, and PSMA5 showing no correlation. 3 Of note, we found that CELSR2 and MYBPHL expression levels were low and could not be reliably measured by quantitative reverse transcriptase-polymerase chain reaction in primary human hepatocytes and BAC transgenic mice (ie, high C t values), and so they were not analyzed for this study.
We initially screened primary human hepatocytes from 20 individuals for rs12740374 genotype, plated in triplicate format. Six of the lots were heterozygous and 14 were homozygous for the major allele; none were homozygous for the minor allele. Three days after plating, we found that the heterozygous cells, with 1 copy of the putative transcriptional enhancer, had 10.5-fold higher SORT1 expression on average compared with homozygous major cells (P=0.0006) as assessed by quantitative reverse transcriptase-polymerase chain reaction, signifying strong replication of the previously observed liver-specific eQTL ( Figure 1B ). We also observed 1.8-fold higher PSRC1 expression (P=0.05; Figure 1C ). Of note, these findings do not establish that rs12740374 is the causal variant responsible for the increased SORT1 and PSRC1 expression in the heterozygous cells; rather, rs12740374 is a tag SNP for the haplotype of the SORT1 locus, with any of the SNPs in the minor haplotype potentially being the causal variant.
In a recent report, HLCs derived from 17 individuals homozygous for the rs12740374 minor allele and 17 individuals homozygous for the rs12740374 major allele were compared with respect to SORT1 expression. 7 By quantitative reverse transcriptase-polymerase chain reaction, there was only a 1.3-fold increase in SORT1 expression in the homozygous minor HLCs, with nominal statistical significance (P=0.05). Given the enormous discrepancy between this finding and our finding in the primary human hepatocytes, we assessed the rs12740374-SORT1 eQTL in a much larger population cohort of induced pluripotent stem cell-derived HLC samples (n=86 individuals). 8 Using RNA-seq data from the HLC cohort, we observed only a weak relationship between rs12740374 genotype and SORT1 expression, with nominal statistical significance (P=0.05; Figure I in the online-only Data Supplement). By way of direct comparison, we used RNA-seq data from the whole-liver cohort of the GTEx project (n=96) and observed a strong rs12740374-SORT1 eQTL (P=7×10 −18 ; Figure I in the online-only Data Supplement). We also used quantitative reverse transcriptase-polymerase chain reaction to assess SORT1 and PSRC1 expression in the HLC cohort and confirmed that the differences between heterozygous HLCs (n=27) and major allele homozygous HLCs (n=55) were small (for SORT1, 1.7-fold increase, P=0.15; for PSRC1, no increase, P=0.94) in direct comparison with the differences observed in primary human hepatocytes ( Figure 1B and 1C) .
Given the poor replication of the rs12740374-SORT1 eQTL in 2 different HLC cohorts, we chose to instead use the primary human hepatocytes to attempt functional validation of the rs12740374 minor allele sequence as a transcriptional enhancer of SORT1 expression, using CRISPR-Cas9 to disrupt the sequence. To achieve genome editing of the rs12740374 minor allele sequence, we used a validated guide RNA designed to cleave 1 bp upstream of rs12740374, with a protospacer overlapping the position of rs12740374 and complementary to the minor allele of the SNP (Figure 2A ). In principle, this guide RNA should target Cas9 specifically to a chromosome with the minor allele of rs12740374 and spare a chromosome with the major allele. We recognized that genome editing of primary human hepatocytes would be challenging because of (1) the difficulty of delivering CRISPR-Cas9 into primary cells and (2) the hepatocytes being only rated to survive in culture for 3 days after plating. To assess whether we could achieve a high infection rate of primary human hepatocytes in culture, we treated samples of cells with GFP-encoding adenovirus 1 day after plating and observed GFP expression in virtually all of the cells on the third day ( Figure II in the online-only Data Supplement). We treated replicates of the heterozygous human hepatocytes with either the CRISPR-SNP adenovirus or the CRISPR-control adenovirus 1 day after plating and harvested the cells on the third day, allowing for only ≈48 hours of expression of the CRISPR-Cas9 system in the cells. We performed deep sequencing of the rs12740374 site in a representative sample, which demonstrated (1) essentially exclusive targeting of minor allele-bearing chromosomes in preference to major allele-bearing chromosomes (>99% proportion) and (2) an estimated 6% indel rate in minor allele-bearing chromosomes (online-only Data Supplement).
Despite the low level of CRISPR-Cas9-mediated mutagenesis, we observed highly reproducible decreases in SORT1 and PSRC1 expression in the CRISPR-SNP-treated cells compared with the CRISPR-control-treated cells ( Figure 2B through 2D) . Each of the 6 lots of heterozygous human hepatocytes, when replicates were averaged, displayed lower expression of both genes with CRISPR-SNP treatment ( Figure 2C and 2D) .
When the data from all of the replicates of all of the lots were aggregated (n=19 pairs across 6 lots), SORT1 expression was reduced by 11% (P=0.0002), and PSRC1 expression was reduced by 20% (P=0.0002; Figure 2B ). We also assessed 2 control genes in the SORT1 locus whose expression levels in liver are not correlated with rs12740374 genotype, SARS and PSMA5. For these genes, there were negligible, nonsignificant differences between the treatment groups ( Figure 2B ).
As a complementary approach, we sought to study the interaction of the rs12740374 minor allele sequence and hepatic SORT1 expression in vivo ( Figure 3A) . Given the lack of conservation of the rs12740374 site in the mouse genome (Figure 2A) , we generated BAC transgenic mice with the human SORT1 locus integrated into the mouse genome. BAC clone RP11-463O24 (boundaries indicated in Figure 1A) , which has the minor allele of rs12740374, was injected into single-cell embryos of the C57BL/6J background, yielding 10 founder mice. On breeding of the mice, we identified the stable transgenic line with the lowest copy number of the complete BAC transgene ( Figure 3B ) and confirmed the presence of the minor allele of rs12740374. We used mice of the F2 generation of this line for somatic in vivo genome-editing experiments.
The CRISPR-SNP adenovirus or the CRISPR-control adenovirus was administered to mice at 2 to 3 months of age. After either 4 days or 2 weeks, we euthanized the mice to harvest liver tissue. Although there was no evidence of mutagenesis in the control mice, the CRISPR-SNP-treated mice displayed consistent and substantial levels of mutagenesis by CEL-I nuclease assay ( Figure 3C ). Deep sequencing of the rs12740374 site in a representative CRISPR-SNP-treated mouse documented a 33% indel rate (online-only Data Supplement)-a degree of mutagenesis concordant with previous studies of in vivo hepatic genome editing with virally delivered CRISPR-Cas9. [9] [10] [11] We observed 60% reduction (4 days) and 58% reduction (2 weeks) in human SORT1 expression in CRISPR-SNP-treated mice compared with CRISPRcontrol-treated mice ( Figure 3D) , with concordant reduction of hepatic sortilin protein levels observed by Western blot analysis ( Figure 3E ). We also observed 30% reduction (4 days; nonsignificant P value) and 42% reduction (2 weeks) in human PSRC1 expression, whereas there was minimal change in expression of the control human SARS gene at either time point (PSMA5 is not contained within the BAC clone RP11-463O24 and so could not be used as an additional control gene). No differences were observed in blood cholesterol levels, as expected from the small effect of rs12740374 in humans (5.65-mg/dL change in cholesterol per allele 1 ). In Figure 2 . Effects of CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) genome editing of the rs12740374 minor allele sequence in primary human hepatocytes. A shows the human rs12740374 minor and major allele sequences and the orthologous sequence in mouse. The rs12740374 single-nucleotide polymorphism (SNP) position is bold and underlined. The C/ EBP (CCAAT enhancer-binding protein) consensus-binding site, intact with the minor allele and disrupted with the major allele, is shown with grey shading. The bottom minor allele sequence is shown as double-strand DNA, with boxes indicating the chosen CRISPR-Cas9 protospacer sequence and protospacer-adjacent motif (PAM) used for the CRISPR-SNP adenovirus. The predicted CRISPR-Cas9 cleavage site is indicated with scissors. B shows the aggregated differences in gene expression between the CRISPR-control-treated and CRISPR-SNP-treated samples within each pair of samples of heterozygous primary human hepatocytes (n=19 pairs total); the aggregated differences are expressed as the means and SEM of the proportions of change. P values were calculated using the Wilcoxon signed-rank test for the 19 pairs for each gene. C and D show the expression levels of SORT1 and PSRC1, normalized to the mean of the expression levels of all of the CRISPR-control-treated samples. The data are displayed as means and SEM for the pairs of samples within each of the 6 heterozygous lots on the top. The same data are shown on the bottom, with the means for the CRISPR-control-treated samples within each of the 6 lots set to zero and the means for the CRISPR-SNP-treated samples of the 6 lots shown as proportional changes from the CRISPR-control-treated samples. The number of sample pairs for each lot is shown at the bottom. Figure 3 . Effects of CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) genome editing of the rs12740374 minor allele sequence in locus-humanized mice. A shows a schematic for the generation and testing of locus-humanized mice. B shows polymerase chain reaction (PCR) assays confirming the presence of the entire bacterial artificial chromosome (BAC) RP11-463O24 (rs12740374 minor allele) insert in the genome in F2 mice. The 11 PCR amplicons shown correspond to the sites of the 11 circles in Figure 1A . C shows CEL-I nuclease assays performed with PCR amplicons around the rs12740374 single-nucleotide polymorphism (SNP) site from liver genomic DNA from locus-humanized mice administered CRISPR-control or CRISPR-SNP adenovirus. Arrows show the cleavage products resulting from the CEL-I nuclease assays; the intensity of the cleavage product bands relative to the uncleaved product band corresponds to the mutagenesis rate. D shows the hepatic expression levels of SORT1, PSRC1, and SARS from the human BAC locus, normalized to the mean of the expression levels of all of the CRISPR-control mice. Left shows hepatic gene expression 4 days after virus treatment (n=5 CRISPR-control mice and 7 CRISPR-SNP mice). The right shows hepatic gene expression 2 weeks after virus treatment (n=4 CRISPR-control mice and 5 CRISPR-SNP mice). The data are displayed as means and SEM for the mice within each treatment group. P values were calculated using the Mann-Whitney U test to compare the 2 treatment groups for each gene. E shows Western blot analysis of sortilin and β-actin in liver samples from the mice represented in the right of D. MW indicates molecular weight. a parallel experiment, we used an adenovirus with a guide RNA similar to the CRISPR-SNP adenovirus but matched to the rs12740374 major allele rather than the minor allele (CRISPR-major adenovirus). Compared with CRISPRcontrol, CRISPR-major produced no discernible mutagenesis and did not decrease SORT1 or PSRC1 expression after 2 weeks ( Figure III in the online-only Data Supplement).
Discussion
Our motivation to compare 3 different hepatocyte model systems came from recognition of the shortcomings of available model systems. Cultured human hepatoma cell lines have profound karyotypic abnormalities and do not faithfully replicate many aspects of hepatocyte biology. 12 Even if they did represent authentic hepatocytes, none of the commonly used hepatoma cell lines are homozygous for the minor allele or even heterozygous at rs12740374. This is a challenge common to any SNP for which the minor allele and not the major allele has biological activity. One could use genome editing to knock in the minor allele at rs12740374 in one of the cell lines, but besides being inefficient because of the limitations of homology-directed repair, this would not address the other problems of hepatoma cells.
In principle, induced pluripotent stem cells have substantial advantages over human hepatoma cell lines: they have normal karyotypes that can be maintained over many passages, even through expansion from a single cell to millions of cells; thousands of induced pluripotent stem cell lines have been made, and so it is feasible to identify existing cell lines that are homozygous minor for a common SNP of interest; they are amenable to genome editing; and they can be readily differentiated into cells resembling hepatocytes. However, such differentiated cells tend to be heterogeneous, immature, and lacking in important aspects of hepatocyte biology. 13 These shortcomings are evident in the inability of HLCs to faithfully model the strong rs12740374-SORT1 eQTL observed in both wholeliver samples and primary human hepatocytes. This has now been observed in 2 separate studies (reference 7 and the current study), despite the investigators generating HLCs with 2 distinct differentiation protocols, with the earlier study using a protocol in which the HLCs were sorted by expression of ASGR1 (hepatocyte-specific marker) in an attempt to obtain more mature cells. 7 We speculate that HLCs lack a factor or factors present in primary human hepatocytes and liver needed to fully reproduce the SORT1 eQTL. It should be noted that HLCs have been observed to faithfully model eQTLs with other lipid-associated genes, for example, the hepatocyte-specific gene ANGPTL3. 8 This suggests that HLCs can be useful for establishing causal SNP-gene relationships for some loci but not for others, and their experimental application to the study of genetic variation should be carefully considered on a case-by-case basis.
Primary human hepatocytes are generally regarded as the gold standard, but they are difficult to procure and for that reason are expensive, which makes performing studies with large numbers of samples prohibitive. Additionally, plated hepatocytes are difficult to maintain in culture, typically surviving for only a few days, 12 which militates against prolonged expression of CRISPR-Cas9 to achieve efficient genome editing. Furthermore, gene delivery into primary human hepatocytes is challenging; this prompted us to deliver CRISPR-Cas9 with adenovirus, which is uniquely efficient and can infect 100% of human hepatocytes in culture. 14, 15 Adenovirus infection can mildly alter some of the properties of cultured hepatocytes; 16 in our experiments, we accounted for this with the use of a control adenovirus. However, we found that even with adenovirus, we achieved a low degree of genome editing in the hepatocytes, which raises the question of their general suitability for the study of SNP variants with modest effects on gene expression and other phenotypes.
Although our experiments with primary human hepatocytes provided clear evidence that the rs12740374 minor allele sequence enhances SORT1 expression, the limitations of the approach argued for a complementary strategy to assess the function of noncoding regulatory regions in hepatocytes. The downsides of studying hepatocytes or HLCs in culture make studying authentic hepatocytes in vivo in an animal model attractive. In the case of rs12740374 (as is the case with most of the noncoding variants identified in genome-wide association studies), the lack of conservation in the mouse genome required us to introduce the human SORT1 locus via BAC transgenesis. One disadvantage of this approach is that the BAC incorporates in an uncontrolled manner into the genome, that is, a random insertion site. Although the large size of the BAC guards against position effects, that is, the influence of surrounding DNA elements and chromatin structure on gene expression from within the transgene, 17 it does not eliminate the possibility. 18 Ideally, one would wish to cleanly replace the orthologous mouse locus with the human locus, so that the human locus lies in the appropriate genomic context, but this remains a considerable technical challenge. 19 Another issue with studying a human locus in the mouse genome is the assumption that the transcriptional regulatory machinery is conserved between human and mouse (ie, transcription factors have the same sequence specificity, have the same binding partners, etc). Although this may be a reasonable assumption a priori, there is little existing information that bears on the validity of this assumption. Indeed, our finding that the rs12740374 minor allele sequence transcriptionally enhances hepatic SORT1 expression in the locus-humanized mouse provides some of the first information suggesting conservation between human and mouse in this respect.
Another strategy to study human loci in hepatocytes would be to generate liver-humanized mice in which endogenous mouse hepatocytes have been replaced with transplanted primary human hepatocytes. 20 Somatic in vivo genome editing of the human hepatocytes in these mice has been demonstrated. 11 The major disadvantage of this strategy is that it requires a large supply of primary human hepatocytes of a defined genotype, which might be difficult to procure. In the case of rs12740374-SORT1, homozygous minor hepatocytes would be optimal for use in liver-humanized mice; CRISPR-SNP adenovirus could be used to disrupt the endogenous minor allele sequences with the expectation of reducing SORT1 expression in the human hepatocytes in vivo. Because we were unable to identify any lot of hepatocytes from a homozygous minor individual, we did not pursue this strategy.
Finally, it is worth noting that although clean knock-in of the major allele to replace the minor allele of rs12740374 in either primary human hepatocytes or the livers of locushumanized mice would have been preferable to disruption of the rs12740374 minor allele sequence, the efficiency of such knock-in (which relies on homology-directed repair) is far lower than the efficiency of disruption with indels (which relies on nonhomologous end joining). As a practical matter, only disruption is feasible in the context of ex vivo targeting of primary cells or somatic in vivo targeting, given the current state of genome-editing technology and in the absence of a method to purify or select for the correct knock-in cells.
With large collaborative efforts, such as genome-wide association studies, the GTEx project, and the ENCODE (Encyclopedia Of DNA Elements) Project, pinpointing numerous candidate noncoding regulatory regions, novel approaches are needed to interrogate whether these regions are causal for gene expression effects and other phenotypes. Here we used CRISPR-Cas9 genome editing in primary human hepatocytes ex vivo and in locus-humanized mice in vivo to address whether a putative regulatory region in the human SORT1 locus is truly causal for liver-specific modulation of SORT1 expression. Experiments in both models confirmed that the rs12740374 minor allele sequence enhances SORT1 expression in hepatocytes. When used judiciously, such models could be broadly useful to assess loci associated with a wide variety of cardiovascular and metabolic traits and diseases.
